NASDAQ:NERV Minerva Neurosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.59 +0.28 (+8.46%) (As of 07/1/2022 03:55 PM ET) Add Compare Share Today's Range$3.56▼$3.7050-Day Range$2.70▼$4.8452-Week Range$2.62▼$19.04Volume400 shsAverage Volume20,100 shsMarket Capitalization$19.17 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Minerva Neurosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,014.2% Upside$40.00 Price TargetShort InterestHealthy1.01% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.56) to ($5.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.25 out of 5 starsMedical Sector228th out of 1,428 stocksPharmaceutical Preparations Industry112th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Minerva Neurosciences has a forecasted upside of 1,014.2% from its current price of $3.59.Amount of Analyst CoverageMinerva Neurosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.01% of the outstanding shares of Minerva Neurosciences have been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 78.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMinerva Neurosciences has received a 71.93% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Clinical research services for Parkinsonism" products. See details.Environmental SustainabilityThe Environmental Impact score for Minerva Neurosciences is -0.75. Previous Next 2.6 News and Social Media Coverage News SentimentMinerva Neurosciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Minerva Neurosciences this week, compared to 0 articles on an average week.Search Interest4 people have searched for NERV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders15.95% of the stock of Minerva Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.59% of the stock of Minerva Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($8.56) to ($5.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMinerva Neurosciences has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Minerva Neurosciences (NASDAQ:NERV) StockMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More NERV Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comStockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)June 24, 2022 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.comJune 22, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn SituationJune 21, 2022 | marketwatch.comMinerva Neurosciences Shares Slip After Reverse Split >NERVJune 15, 2022 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.comJune 9, 2022 | americanbankingnews.comZacks Investment Research Upgrades Minerva Neurosciences (NASDAQ:NERV) to HoldMay 6, 2022 | finanznachrichten.deMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business UpdatesMay 4, 2022 | seekingalpha.comMinerva Neurosciences GAAP EPS of -$0.23 misses by $0.05May 4, 2022 | finance.yahoo.comMinerva Neurosciences Reports First Quarter 2022 Financial Results and Business UpdatesMay 3, 2022 | finance.yahoo.comMinerva Neurosciences, Inc. (NERV)April 7, 2022 | uk.investing.comMinerva Outlines Next Steps For US Application For Schizophrenia CandidateApril 7, 2022 | seekingalpha.comMinerva gets FDA meeting minutes on its treatment for negative symptoms in schizophreniaApril 7, 2022 | finance.yahoo.comMinerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaMarch 21, 2022 | finance.yahoo.comMarinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic DisorderMarch 4, 2022 | benzinga.comHC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to $5March 1, 2022 | seekingalpha.comMinerva Neurosciences GAAP EPS of -$0.50 misses by $0.31March 1, 2022 | finance.yahoo.comMinerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business UpdatesMarch 1, 2022 | finance.yahoo.comMinerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue EstimatesFebruary 28, 2022 | finanznachrichten.deMinerva Neurosciences, Inc: Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia BulletinFebruary 28, 2022 | finance.yahoo.comMinerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia BulletinJanuary 21, 2022 | thestreet.comMinerva Neurosciences (NERV) Stock Price Target Hiked at JefferiesDecember 25, 2021 | nasdaq.comWill Minerva Neurosciences (NASDAQ:NERV) Spend Its Cash Wisely?December 1, 2021 | finance.yahoo.comIs Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?November 8, 2021 | msn.comMinerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue EstimatesNovember 3, 2021 | finance.yahoo.comMinerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA SubmissionSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NERV CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/04/2022Next Earnings (Estimated)8/01/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$40.00 High Stock Price Forecast$40.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+1,014.2%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-193.41% Return on Assets-39.43% Debt Debt-to-Equity RatioN/A Current Ratio17.15 Quick Ratio17.15 Sales & Book Value Annual Sales$41.18 million Price / Sales0.47 Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book2.41Miscellaneous Outstanding Shares5,340,000Free Float4,488,000Market Cap$19.17 million OptionableOptionable Beta1.04 Minerva Neurosciences Frequently Asked Questions Should I buy or sell Minerva Neurosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Minerva Neurosciences stock. View analyst ratings for Minerva Neurosciences or view top-rated stocks. What is Minerva Neurosciences' stock price forecast for 2022? 1 analysts have issued 12-month target prices for Minerva Neurosciences' stock. Their NERV stock forecasts range from $40.00 to $40.00. On average, they anticipate Minerva Neurosciences' share price to reach $40.00 in the next twelve months. This suggests a possible upside of 1,014.2% from the stock's current price. View analysts' price targets for Minerva Neurosciences or view top-rated stocks among Wall Street analysts. How has Minerva Neurosciences' stock performed in 2022? Minerva Neurosciences' stock was trading at $6.4080 on January 1st, 2022. Since then, NERV stock has decreased by 44.0% and is now trading at $3.59. View the best growth stocks for 2022 here. When is Minerva Neurosciences' next earnings date? Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for Minerva Neurosciences. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its quarterly earnings data on Wednesday, May, 4th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.60) by $0.24. View Minerva Neurosciences' earnings history. When did Minerva Neurosciences' stock split? How did Minerva Neurosciences' stock split work? Minerva Neurosciences's stock reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of Minerva Neurosciences stock prior to the reverse split would have 13 shares after the split. Who are Minerva Neurosciences' key executives? Minerva Neurosciences' management team includes the following people: Dr. Remy Luthringer Ph.D., Exec. Chairman & CEO (Age 61, Pay $1.19M)Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA, Pres (Age 61, Pay $880.44k)Mr. Frederick W. Ahlholm CPA, CPA, Sr. VP, CFO & Sec. (Age 56, Pay $610.68k)Dr. Michael Davidson M.D., Chief Medical Officer (Age 72, Pay $657.47k)Mr. Joseph Reilly, Sr. VP & COO (Age 47)Mr. William B. Boni, VP of Investor Relations & Corp. Communications (Age 70)Dr. Jay B. Saoud Ph.D., Consultant (Age 63)Dr. Ramana Kuchibhatla Ph.D., Sr. VP and Head of R&D Who are some of Minerva Neurosciences' key competitors? Some companies that are related to Minerva Neurosciences include HCW Biologics (HCWB), Adamis Pharmaceuticals (ADMP), Synlogic (SYBX), Gemini Therapeutics (GMTX), FoxWayne Enterprises Acquisition (FOXW), Tiziana Life Sciences (TLSA), Equillium (EQ), Bolt Biotherapeutics (BOLT), Akebia Therapeutics (AKBA), Lipocine (LPCN), Qilian International Holding Group (QLI), Seelos Therapeutics (SEEL), Terns Pharmaceuticals (TERN), Sensei Biotherapeutics (SNSE) and Atreca (BCEL). View all of NERV's competitors. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD). What is Minerva Neurosciences' stock symbol? Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV." How do I buy shares of Minerva Neurosciences? Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Minerva Neurosciences' stock price today? One share of NERV stock can currently be purchased for approximately $3.59. How much money does Minerva Neurosciences make? Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $19.17 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($9.60) on an earnings per share basis. How many employees does Minerva Neurosciences have? Minerva Neurosciences employs 9 workers across the globe. How can I contact Minerva Neurosciences? Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for Minerva Neurosciences is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com. This page (NASDAQ:NERV) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
